Sam Kintz News Today

Enliven Therapeutics Inc. (Nasdaq: ELVN), a Boulder clinical-stage precision oncology company, has enough cash on hand to fund operations into late 2026, the company disclosed this week, and through multiple milestones for two of its drug candidates.

Achieved initial cumulative MMR rate of 44% by 12 weeks in response-evaluable patients, which compares favorably to precedent Phase 1 trials of approved BCR::ABL1 TKIs Achieved initial cumulative...

Achieved initial cumulative MMR rate of 44% (7/16) by 12 weeks in response-evaluable patients, which compares favorably to precedent Phase 1 trials of...

BOULDER, Colo., April 09, 2024 (GLOBE NEWSWIRE) -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage precisio...

Enliven Therapeutics Inc. roughly doubled its year-over-year net losses as advances in its drug-development pipeline have resulted in increased research and development costs.

Enliven Therapeutics’ reverse merger with Imara will form a combined company with $300 million to finance clinical development of new cancer drugs. Its most advanced program is a tyrosine kinase inhibitor for chronic myeloid leukemia.

BioPharma

Concurrent with the merger, Enliven plans to raise $165 million in a private financing, and the joint company is expected to have $300 million in cash and cash equivalents.